Workflow
Eli Lilly (LLY) Q4 Earnings and Revenues Top Estimates
LLYLilly(LLY) ZACKS·2025-02-06 13:56

Core Viewpoint - Eli Lilly reported quarterly earnings of 5.32pershare,exceedingtheZacksConsensusEstimateof5.32 per share, exceeding the Zacks Consensus Estimate of 5.03 per share, and showing significant growth from 2.49pershareayearago,indicatingastrongperformanceinthepharmaceuticalsector[1][2].FinancialPerformance−Thecompanyachievedrevenuesof2.49 per share a year ago, indicating a strong performance in the pharmaceutical sector [1][2]. Financial Performance - The company achieved revenues of 13.53 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.44%, and up from 9.35billionyear−over−year[2].−Overthelastfourquarters,EliLillyhassurpassedconsensusEPSestimatesthreetimesandtoppedrevenueestimatestwotimes[2].StockPerformance−EliLillyshareshaveincreasedapproximately9.19.35 billion year-over-year [2]. - Over the last four quarters, Eli Lilly has surpassed consensus EPS estimates three times and topped revenue estimates two times [2]. Stock Performance - Eli Lilly shares have increased approximately 9.1% since the beginning of the year, outperforming the S&P 500's gain of 3.1% [3]. - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is 4.72 on revenues of 12.7billion,andforthecurrentfiscalyear,itis12.7 billion, and for the current fiscal year, it is 23.79 on revenues of $59.63 billion [7]. - The trend of estimate revisions for Eli Lilly is mixed, which could change following the recent earnings report [6]. Industry Context - The Large Cap Pharmaceuticals industry is currently ranked in the bottom 31% of over 250 Zacks industries, suggesting potential challenges ahead [8].